Masato Mizuashi

Masato Mizuashi

Auto-generated profile, based on publicly available information

Masato Mizuashi

Tohoku University Graduate School of Medicine Sendai Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2022 in Science Immunology
Verified
Journal Article
Closed access
HITOSHI TERUIHITOSHI TERUI
HITOSHI TERUI
KYKenshi Yamasaki
Kenshi Yamasaki
MWMoyuka Wada-Irimada
Moyuka Wada-Irimada
MOMayuko Onodera-Amagai
Mayuko Onodera-Amagai
NHNaokazu Hatchome
Naokazu Hatchome
SASetsuya Aiba
Setsuya Aiba
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by inflammation of various organs such as skin, kidneys, bones, and brain and the presence of autoantibodies. Although the cause of SLE is not completely understood, environmental factors, genetic susceptibility, hormone factors, and environmental factors are thought to play essential roles in the pathogenesis of SLE. Among environmental factors, the microbiota are linked to the development of different autoimmune diseases. The microbiota in the nasal cavity and gut are involved in SLE development, but the influence of skin microbiota is still unclear. Here, we demonstrated that epithelial cell–specific IκBζ-deficient ( Nfkbiz ΔK5 ) mice showed spontaneous skin inflammation with increased abundance of Staphylococcus aureus on the skin. When S. aureus was epicutaneously applied on Nfkbiz ΔK5 mice, Nfkbiz ΔK5 mice developed SLE-associated autoantibodies, anti-dsDNA antibodies, anti-Sm antibodies, and glomerulonephritis with IgG deposition. Epicutaneous S. aureus application significantly increased staphylococcal colonization on the skin of Nfkbiz ΔK5 mice with reduced expression of several antimicrobial peptides in the skin. This staphylococcal skin colonization promoted caspase-mediated keratinocyte apoptosis and neutrophil activation, inducing the interleukin-23 (IL-23)/IL-17 immune response by activating dendritic cells and T cells. Furthermore, the subcutaneous administration of anti–IL-23p19 and anti–IL-17A antibodies alleviated the systemic autoimmune response. Together, these findings underscore epithelial-immune cross-talk disturbances caused by skin dysbiosis as an essential mediator inducing autoimmune diseases.

27 September 2024 in The Journal of Dermatology
Verified
Journal Article
Open access
NMNatasha Mesinkovska
Natasha Mesinkovska
BKBrett King
Brett King
XZXingqi Zhang
Xingqi Zhang
EGEmma Guttman‐Yassky
Emma Guttman‐Yassky
NMNina Magnolo
Nina Magnolo
GSGregor Schaefer
Gregor Schaefer
This post‐hoc analysis of the ALLEGRO phase 2b/3 study (NCT03732807) evaluated the efficacy and safety of ritlecitinib, an oral Janus kinase 3/TEC family kinase inhibitor, in patients with alopecia totalis (AT) and alopecia universalis (AU). Patients aged ≥ 12 years with alopecia areata (AA) and ≥50% scalp hair loss received once‐daily ritlecitinib 50 or 30 mg (± 4‐week 200‐mg loading dose) or placebo for 24 weeks. In a subsequent 24‐week extension period, the ritlecitinib groups continued their doses and patients initially assigned to placebo switched to ritlecitinib (200/50 or 50 mg daily). In this analysis, clinician‐ and patient‐reported hair regrowth outcomes were assessed at weeks 24 and 48 in four AA subgroups: AT/AU, AT, AU, and non‐AT/AU. Safety was monitored throughout. Of the 718 randomized patients, 151 (21%) and 147 (20%) were defined as having AT or AU, respectively. At week 24, Severity of Alopecia Tool (SALT) score ≤20 (≤20% scalp hair loss) response rates were higher in the ritlecitinib‐treated AT/AU, AT, and AU groups (7%–14%, 7%–21%, and 4%–10%, respectively) vs the placebo group (0% in the AT/AU, AT, and AU groups). The proportions of patients with a SALT score of ≤20 increased through week 48 (AT/AU, 13%–31%; AT, 11%–27%; AU, 6%–41%). Additionally, at week 24, 25%–43%, 32%–42%, and 12%–50% of patients with AT/AU, AT, and AU, respectively, who received ritlecitinib achieved a moderately or greatly improved response based on the Patient Global Impression of Change scale. Response rates generally increased through week 48 and were similar across AA subgroups. In patients with AT/AU, ritlecitinib was well tolerated with a safety profile consistent with that of the overall AA population. Ritlecitinib demonstrated clinical efficacy, patient‐reported improvement, and an acceptable safety profile in patients with AT and AU through week 48. A plain language summary of this study is available at https://doi.org/10.25454/pfizer.figshare.26879161. Clinicaltrials.gov: NCT03732807.

13 July 2021 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
MWM. Wada‐Irimada
M. Wada‐Irimada
MMM. Mizuashi
M. Mizuashi
Toshiya TakahashiToshiya Takahashi
Toshiya Takahashi
GTG. Tojo
G. Tojo
KOK. Onami
K. Onami
KYKenshi Yamasaki
Kenshi Yamasaki

20 June 2025 in The Journal of Dermatology
Verified
Journal Article
Closed access
MWMoyuka Wada‐Irimada
Moyuka Wada‐Irimada
TTTakehiro Takahashi
Takehiro Takahashi
MSMana Sekine
Mana Sekine
TOToshiki Okazaki
Toshiki Okazaki
TTTakuya Takahashi
Takuya Takahashi
YAYoshihide Asano
Yoshihide Asano

23 July 2025 in The Journal of Dermatology
Verified
Journal Article
Closed access
MOManabu Ohyama
Manabu Ohyama
TITaisuke Ito
Taisuke Ito
YAYasuyuki Amoh
Yasuyuki Amoh
SIShigeki Inui
Shigeki Inui
HIHisayoshi Imanishi
Hisayoshi Imanishi
YSYutaka Shimomura
Yutaka Shimomura

6 February 2026 in The Journal of Dermatology
Verified
Journal Article
Open access
RURie Ueki
Rie Ueki
MMMasato Mizuashi
Masato Mizuashi
KHKazutoshi Harada
Kazutoshi Harada
XZXingqi Zhang
Xingqi Zhang
WWWenyu Wu
Wenyu Wu
THTomohiro Hirose
Tomohiro Hirose
Ritlecitinib is an oral JAK3/TEC family kinase inhibitor approved for individuals aged ≥ 12 years with severe alopecia areata. Here we report interim efficacy and safety results with ritlecitinib up to Month 24 in the Asian subpopulation from the ALLEGRO phase 2b/3 and ALLEGRO‐LT studies. Data are reported for participants with Severity of Alopecia Tool score ≥ 50 who received ritlecitinib 50 mg with (200/50‐mg group) or without (50‐mg group) an initial 4‐week 200‐mg daily loading dose in ALLEGRO‐2b/3, and continued ritlecitinib 50 mg in ALLEGRO‐LT. In long‐term studies, it is common for summaries at later time points to reflect participants who remained in the study, tolerated the drug, and had a positive treatment response. To account for this, efficacy summaries were presented both as observed and by using the last observation carried forward method. At Month 12, 51.7% and 44.7% (last observation carried forward) of Asian participants in the 50‐mg ( n = 58) and 200/50‐mg groups ( n = 47), respectively, achieved Severity of Alopecia Tool score ≤ 20 (≤ 20% scalp hair loss); the respective proportions were 50.0% and 47.8% at Month 24. Of participants who achieved Severity of Alopecia Tool score ≤ 20 at Month 12 in the 50‐mg and 200/50‐mg groups, 68.2% and 86.7% sustained this response through Month 24, respectively. At Month 12, 74.0% and 57.9% of participants in the 50‐mg and 200/50‐mg groups, respectively, had an eyebrow hair regrowth response; at Month 24, the proportions were 72.0% and 48.7%. At Month 12, 65.1% and 54.1% of participants in the 50‐mg and 200/50‐mg groups, respectively, had an eyelash hair regrowth response; the proportions were 65.1% and 52.8% at Month 24. The proportion of participants with a Patients' Global Impression of Change response of “moderately” or “greatly” improved since baseline increased through Month 24 in both groups. Ritlecitinib had an acceptable safety profile, consistent with that in the overall population. Overall, ritlecitinib 50 mg (±200‐mg loading dose) demonstrated clinically meaningful and sustained efficacy through Month 24 in the Asian subpopulation, consistent with results in the overall population. Trial Registration: ClinicalTrials.gov : NCT04006457.